Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 14/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120843 | 0.80 | GPR17 (0.42) | GPR17MCL1NR3C1 | |
| SCHEMBL1120840 | 0.78 | ADRB3 (0.61) | — | |
| SCHEMBL1120832 | 0.73 | MCL1 (0.40) | MCL1NR3C1 | |
| SCHEMBL1120831 | 0.71 | ADRB3 (0.61) | — | |
| SCHEMBL1120786 | 0.70 | NR3C1 (0.45) | GPR17MCL1NR3C1 | |
| SCHEMBL1120844 | 0.68 | ADRB3 (0.65) | — | |
| SCHEMBL1120845 | 0.68 | ADRB3 (0.65) | — | |
| SCHEMBL1120785 | 0.67 | ADRB3 (0.63) | — | |
| SCHEMBL6740388 | 0.66 | ADRB3 (0.53) | — | |
| SCHEMBL7781344 | 0.65 | ADRB2 (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511069-B2 | Indazole compounds as β3 andrenoceptor agonist | ASAHI PHARMA CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | GPR17 878/4885MCL1 4013/4885KDM4E 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.